Drug · Monoclonal Antibody

Bevacizumab

CI-DRUG-00000107Explore in graph →NCIt C2039 CHEMBL1201583 CIViC Approved

Regulatory

Approvals (52)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

emaRegulatory12 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
EU EMA	—	Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. first line treatment of patients with advanced and/or metastatic renal cell cancer.	approved	Jul 26, 2024	ema
EU EMA	—	VEGZELMA in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. VEGZELMA in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. VEGZELMA in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with VEGZELMA in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. VEGZELMA, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (NSCLC) other than predominantly squamous cell histology. VEGZELMA, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). VEGZELMA, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. VEGZELMA, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). VEGZELMA, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor–targeted agents. VEGZELMA in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1). VEGZELMA, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 17 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	439	248	274	1,770	52	CA, EU, US	Feb 26, 2004	1997-07
Malignant Liver Neoplasm	Approved	Phase 4	62	33	22	125	1	US	Feb 26, 2004	2003-02
Malignant Lung Neoplasm	Approved	Phase 4	38	22	39	227	1	US	Feb 26, 2004	2001-11
Malignant Central Nervous System Neoplasm	Approved	Phase 3	24	12	12	139

Curated evidence

Clinical evidence (48)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–48 of 48 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MMP2 SERUM LEVELS2
Bevacizumab	Breast Inflammatory Carcinoma

Clinical trials

Trials with this intervention (1,821)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1,801–1,821 of 1,821 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00434356	A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)	terminated	Phase 2	46	Genentech, Inc.INDUSTRY	0	Dec 3, 2009	clinicaltrials
NCT00165568	Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: Vascular endothelial growth factor A inhibitor
Targets: 1 gene
UNII: 2S9ZZM9Q9V
Aliases: 12-IGG1, Abevmy, ABP 215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF RhuMAb, AVA-1, Avastin, AVASTIN, Avegra, Avzivi, Aybintio, BAMBEVI, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab, Bevacizumab-adcd, Bevacizumab (avastin), Bevacizumab-aveg, Bevacizumab Awwb, Bevacizumab-aybi, Bevacizumab beta, Bevacizumab Biosimilar ABP 215, Bevacizumab biosimilar (amgen), Bevacizumab Biosimilar BAT1706 … (+98)

Data updated 20 hours agoSource updated unknown

Identifiers

Codes (44)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FG01	BEVACIZUMAB
ATC (WHO)	L01XC07

VEGFA Overexpression4
Bevacizumab	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID7013 We found that high VEGF expression (mean positive area > 5,000 pixels/×400 field) was associated with increased likelihood of achieving radiographic response (P = .024; Table 2). PMID 18182667 · Sathornsumetee et al., 2008 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	3	submitted	EID9229 A meta analysis and systematic review of three trials with a total of 3748 breast cancer patients was undertaken to determine if VEGF-A plasma levels affected patient outcomes in response to bevacizum… (full text at CIViC) PMID 25947646 · Santos et al., 2015 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	2	submitted	EID7216 Patients with high baseline plasma VEGF-A levels showed a trend toward improved overall survival (hazard ratio [HR], 0.72; 95% CI, 0.57 to 0.93) versus patients with low VEGF-A levels (HR, 1.01; 95% C… (full text at CIViC) PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC	civic
Bevacizumab + ErlotinibCombination	Malignant Ovarian Neoplasm	Predictive	B	Supports Resistance	2	submitted	EID7237 This phase II trial evaluated the efficacy of bevacizumab+erlotinib in 40 platinum-resistant ovarian cancer patients. No evidence was found associating VEGFR-1 expression and any clinical parameters.… (full text at CIViC) PMID 21041183 · Chambers et al., 2010 · Open in CIViC	civic

VEGFA Overexpression of VEGF1212
Bevacizumab	GlioblastomaCURATED_BROADER	Predictive	B	Supports Resistance	4	submitted	EID9490 In a clinical study including 12 patients already treated with bevacizumab, high levels of plasma VEGF-121 decrease the OS and the PFS (p = 0.0246 and p = 0.0295) compared to low level of expression. PMID 29747600 · Martini et al., 2018 · Open in CIViC	civic
〃	HER2 Negative Breast CancerUNRESOLVED	Predictive	B	Supports Sensitivity Response	3	submitted	EID9297 Patients with high plasma VEGF121 levels treated with bevacizumab compared to placebo showed a trend toward improved PFS (HR 0.52; 95% CI, 0.33 to 0.81). The trend was not significant with patients wi… (full text at CIViC) PMID 23422754 · Miles et al., 2013 · Open in CIViC	civic

FH Deficient2
Bevacizumab + ErlotinibCombination	Hereditary Renal Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID12939 In the open‑label phase II AVATAR trial (NCT01130519), patients with HLRCC‑associated papillary RCC harboring germline FH pathogenic variants (n = 43) received erlotinib plus bevacizumab, with ORR as … (full text at CIViC) PMID 40532152 · Srinivasan et al., 2025 · Open in CIViC	civic
〃	Papillary Renal Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID12940 In the open‑label phase II AVATAR trial (NCT01130519), patients with sporadic papillary RCC (n = 40) received erlotinib plus bevacizumab, with ORR as the primary endpoint. They demonstrated a lower OR… (full text at CIViC) PMID 40532152 · Srinivasan et al., 2025 · Open in CIViC	civic

IDH1 R1322
Bevacizumab	High-Grade Glioma, NOS	Predictive	B	Supports Sensitivity Response	2	submitted	EID2330 In a clinical study of 63 recurrent glioma patients, patients treated with bevacizumab monotherapy (n=11) and harboring IDH1 codon 132 mutation were associated with improved progression free survival … (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic
Bevacizumab + SunitinibSubstitutes	High-Grade Glioma, NOS	Predictive	B	Supports Sensitivity Response	2	accepted	EID2020 In a clinical study of 63 recurrent glioma patients, the combined cohort of patients treated with either bevacizumab or sunitinib showed that those harboring IDH1 codon 132 mutation were associated wi… (full text at CIViC) PMID 22199315 · Lv et al., 2011 · Open in CIViC	civic

VEGFA Overexpression of VEGF121 and VEGF1104
Bevacizumab	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	submitted	EID9299 Patients with high VEGF121and VEGF110 levels treated with bevacizumab and chemotherapy compared to chemotherapy only show a trend toward improved PFS. However this trend is not significant (HR 0.64; 9… (full text at CIViC) PMID 23932548 · Cameron et al., 2013 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	4	submitted	EID9300 Patients with high VEGF121and VEGF110 levels treated with bevacizumab compared to placebo show a trend toward improved PFS (HR 0.64, 95% CI, 0.47 to 0.88). The trend was not significant for patients w… (full text at CIViC) PMID 27817944 · Miles et al., 2017 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	submitted	EID9301 In a clinical trial of 161 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab plus trastuzumab plus docetaxel compared to trastuzumab plus docetaxel only show a tr… (full text at CIViC) PMID 23569311 · Gianni et al., 2013 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	3	submitted	EID9298 In a clinical trials of 774 patients, patients with high plasma VEGF121 and VEGF110 levels treated with bevacizumab compared to placebo showed a trend toward improved OS (HR 0.72; 95% CI, 0.57 to 0.93… (full text at CIViC) PMID 22565005 · Van Cutsem et al., 2012 · Open in CIViC	civic

BRAF V600E4
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	submitted	EID2120 Of metastatic colorectal cancer patients treated with bevacizumab-based first-line therapy, those with BRAF V600E mutations had reduced progression-free survival compared to those with wildtype BRAF (… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
Bevacizumab + Capecitabine + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID2121 In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=… (full text at CIViC) PMID 19571295 · Tol et al., 2009 · Open in CIViC	civic
Bevacizumab + Capecitabine + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID98 This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the… (full text at CIViC) PMID 22180495 · Yang et al., 2012 · Open in CIViC	civic
Bevacizumab + Capecitabine + Cetuximab + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	submitted	EID8646 In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, bevacizumab, and cetuximab those with BRAF V600E mutations had reduced progression-free survival (6.6mo vs. … (full text at CIViC) PMID 19571295 · Tol et al., 2009 · Open in CIViC	civic

BRAF Fusion2
Bevacizumab + Sorafenib + TemsirolimusCombination	Spindle Cell Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1664 A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinas… (full text at CIViC) PMID 24422672 · Subbiah et al., 2014 · Open in CIViC	civic
〃	Spindle Cell Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID7312 A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus. Tumor of th… (full text at CIViC) PMID 26314551 · Ross et al., 2016 · Open in CIViC	civic